ArticlePharmaceutical research2026
Innovative Production of Diclofenac Sodium-Loaded Solid Lipid Nanoparticles by Membrane Nanoprecipitation: Evaluation of Encapsulation Efficiency and Photoprotection Ability.
Article in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe stability of diclofenac sodium (DS) in liquid formulation is influenced by environmental factors such as temperature, humidity and light. The encapsulation of this drug in solid lipid nanoparticles (SLNs) can offer a useful strategy to protect it from degradation. The present study shows the potential of membrane nanoprecipitation (MN) as a productive and advantageous method for the formulation of cocoa butter-based SLNs to improve the photostability of DS.
methodsConventional batch nanoprecipitation and MN were explored by varying the formulation parameters and process conditions to obtain SLNs.
resultsThe MN produced SLNs with an average size of 421 ± 14 nm, a high encapsulation efficiency of 95 ± 3.2%, and a drug loading of 8.8 ± 0.2%, when an acetate buffer at pH 4.1 was used as the non-solvent phase. Chemical characterization of the proposed formulation was performed by DSC and FTIR analyses. The efficacy of SLNs in preserving DS stability was investigated under simulated sunlight exposure, demonstrating a residual drug concentration of 90% after 3.34 min with respect to the aqueous solution that showed the same concentration value after 0.072 min.
conclusionsOverall, MN represents a suitable and sustainable process for the continuous production of light-stable drug-loaded SLNs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.